Therapeutic Outcome of >10 Cycles of Cabazitaxel for Castration-resistant Prostate Cancer: A Multi-institutional Study | Anticancer Research
Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial - European Urology
Optimal Timing of Cabazitaxel Introduction for Japanese Patients With Metastatic Castration-resistant Prostate Cancer | Anticancer Research
Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort | British Journal of Cancer
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial - Annals of Oncology
Robust Data and Multivariate Analyses Support Cabazitaxel as a Standard of Care in mCRPC
Progression-free survival (PFS) after cabazitaxel treatment. a PFS in... | Download Scientific Diagram
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort | British Journal of Cancer
Early serum and hematological variables recorded after 3 cycles of... | Download Scientific Diagram
Overall survival (OS) after cabazitaxel treatment. a OS in the... | Download Scientific Diagram
Jevtana: new option for metastatic prostate cancer | MIMS online
Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel | Anticancer Research
ESMO 2021: A Prospective Phase II Trial of Cabazitaxel in Male Patients with Chemotherapy Pre-Treated Metastatic Germ-Cell Tumors: The CABA-GCT Study
1415-Prostate metastatic cabazitaxel three weekly and prednisolone | eviQ
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial - Annals of Oncology
Progression-free survival Kaplan-Meier estimates of the probability of... | Download Scientific Diagram
Cabazitaxel for the treatment of castration-resistant prostate cancer | Future Oncology
Cabazitaxel shows a consistently greater survival benefit compared to mitoxantrone in patients with mCRPC | de Bono | Nowotwory. Journal of Oncology
Clinical Trial Results for JEVTANA® (cabazitaxel) Injection
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer | NEJM
The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients | BMC Cancer | Full Text
Kaplan-Meier estimates of the probability of overall survival (OS) and... | Download Scientific Diagram
ASCO 2020: CARD: Overall Survival Analysis of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel versus Abiraterone
